Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

被引：0
|
作者：
Hanne Vos
Kathleen Lambein
François Richard
Bram Mariën
Ines Nevelsteen
Kevin Punie
Hans Wildiers
Lieze Berben
Annouschka Laenen
Giuseppe Floris
Christine Desmedt
Ann Smeets
机构：
[1] University Hospitals Leuven; Department of Oncology,Department of Surgical Oncology
[2] KU Leuven,Laboratory for Translational Breast Cancer Research, Department of Oncology
[3] KU Leuven,Multidisciplinary Breast Centre
[4] University Hospitals Leuven,Laboratory of Experimental Oncology, Department of General Medical Oncology
[5] University Hospitals Leuven,Leuven Biostatistics and Statistical Bioinformatics Centre (L
[6] KU Leuven,BioStat)
[7] KU Leuven,Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, University Hospitals Leuven
[8] KU Leuven,undefined
来源：
npj Breast Cancer | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
引用
收藏
相关论文
共 50 条
  • [21] Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer
    Osborne, Cynthia
    Challagalla, Jagathi D.
    Eisenbeis, Charles F.
    Holmes, Frankie Ann
    Neubauer, Marcus A.
    Koutrelakos, Nicholas W.
    Taboada, Carlos A.
    Vukelja, Sasha J.
    Wilks, Sharon T.
    Allison, Mary Ann
    Reddy, Praveen
    Sedlacek, Scot
    Wang, Yunfei
    Asmar, Lina
    O'Shaughnessy, Joyce
    CLINICAL BREAST CANCER, 2018, 18 (01) : E89 - E95
  • [22] DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer
    Debien, Veronique
    Adam, Virginie
    Coart, Elisabeth
    Agostinetto, Elisa
    Goulioti, Theodora
    Molinelli, Chiara
    Arahmani, Amal
    Zoppoli, Gabriele
    Piccart, Martine
    FUTURE ONCOLOGY, 2023, 19 (24) : 1655 - 1667
  • [23] PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR EXPRESSION IN HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER
    Kucukzeybek, Betul Bolat
    Bayoglu, Ibrahim V.
    Kucukzeybek, Yuksel
    Yildiz, Yasar
    Oflazoglu, Utku
    Atahan, Murat K.
    Taskaynatan, Halil
    Alacacioglu, Ahmet
    Yigit, Seyran
    Tarhan, Mustafa O.
    POLISH JOURNAL OF PATHOLOGY, 2018, 69 (02) : 157 - 168
  • [24] Prognostic Significance of Single Progesterone Receptor Positivity A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
    Fan, Ying
    Ding, Xiaoyan
    Xu, Binghe
    Ma, Fei
    Yuan, Peng
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Luo, Yang
    MEDICINE, 2015, 94 (46) : e2066
  • [25] Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Hoon, Siao-Nge
    Lau, Peter K. H.
    White, Alison M.
    Bulsara, Max K.
    Banks, Patricia D.
    Redfern, Andrew D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (05):
  • [26] Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
    Marks, Douglas K.
    Gartrell, Robyn D.
    El Asmar, Margueritta
    Boboila, Shuobo
    Hart, Thomas
    Lu, Yan
    Pan, Qingfei
    Yu, Jiyang
    Hibshoosh, Hanina
    Guo, Hua
    Andreopoulou, Eleni
    Wiechmann, Lisa
    Crew, Katherine
    Sparano, Joseph
    Hershman, Dawn
    Connolly, Eileen
    Saenger, Yvonne
    Kalinsky, Kevin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer
    Altundag, Kadri
    MEDICAL ONCOLOGY, 2024, 41 (06)
  • [28] Comparison of EndoPredict and MammaPrint in hormone receptor positive, HER2 negative breast cancer
    Boesl, A.
    Spitzmueller, A.
    Haid, A.
    Jasarevic, Z.
    Baruschke, K.
    Jaeger, S.
    Offner, F.
    BREAST, 2015, 24 : S46 - S47
  • [29] Updates in HER2-Positive and Triple-Negative Breast Cancers
    Telli, Melinda L.
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 605 - 609
  • [30] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345